The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound suitable for the treatment of nocturia.Extensive and intensive studies have been made on compounds capable of inhibiting placental leucineaminopeptidase (P-LAP), in the anticipation that an antidiuretic activity associated with the maintenance of or increase in an endogenous AVP concentration can be exerted by inhibiting P-LAP, which is a metabolic enzyme for AVP, in the nighttime and the urination frequency in the nighttime can be decreased through the antidiuretic activity. As a result, it is found that a (2R)-3-amino-2-(bicyclic pyridylmethyl)-2-hydroxypropanoic acid derivative has a good P-LAP inhibition activity, and it is also found that, in an antidiuretic test using a drinking water-fed rat, the compound has a urine production inhibition activity associated with the increase in an endogenous AVP concentration which is resulted from the P-LAP inhibition by the compound. Thus, the present invention provides a compound which is expected to be used as a therapeutic agent for nocturia and of which the mechanism of action against nocturia is through the inhibition of P-LAP.La présente invention aborde le problème de la production dune composition pharmaceutique, en particulier un composé approprié au traitement de la polyurie nocturne. Des études étendues et approfondies ont été faites sur des composés capables dinhiber la leucine-aminopeptidase placentaire (P-LAP), dans lanticipation quune activité antidiurétique associée au maintien ou à laugmentation dune concentration dAVP endogène peut être exercée par inhibition de la P-LAP, qui est une enzyme métabolique de lAVP, pendant la nuit et la fréquence de miction pendant la nuit peut être réduite par lactivité antidiurétique.En conséquence, il a été découvert quun dérivé de lacide (2R)-3-amino-2-(pyridylméthyl bicyclique)-2-hydroxypropanoïque présente une bonne activité dinhibition de la P-LAP, et il a éga
